EdiGene
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building 2 22 Science Park Road Zhonggua...Phone Number
+86 1080733899Website
www.edigene.comRevenue
$29.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About EdiGene
EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. Established in 2015, EdiGene is headquartered in Beijing, China.Explore more
EdiGene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EdiGene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if EdiGene has recently received funding, and reach out quickly before it becomes old news!
EdiGene, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at EdiGene
Product Launch: Get notified when EdiGene launches new products
Check out if EdiGene is spiking on competitors!
Funding: Get notified immidiatlly once EdiGene has new funding data
Earning: See what the market has to say on EdiGene recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if EdiGene had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
EdiGene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
EdiGene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about EdiGene.
EdiGene financials insights
Gather financial insights about EdiGene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$14.5M
2019
Other Financing Round
$11M
2021
Series B
$129M
EdiGene Tech Stack
A closer look at the technologies used by EdiGene
Most Recent Scoops
Facilities Relocation / Expansion
EdiGene is planning to move its offices in July 2022. The move will impact employees at their existing office located at R&D Center, 2A, Cambridge, MA.
Facilities Relocation/Expansion
Funding
Funding
Funding
Partnership
Funding
Funding
EdiGene News & Media
EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia
BEIJING & WALTHAM, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it had completed the last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent β-thalassemia (TDT). “The dosing of the 8th and last patient in our multi-center Phase I stuEdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies
BEIJING & WALTHAM, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating its gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass. to advance proprietary LEAPER™ technology into transformative in vivo RNA editing therapies with an initial focus on ophthalmology and the cEdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing Hematopoietic Stem Cell Therapy, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent β-thalassemia (TDT) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10-13, 2022 iEdiGene to Present getools, a Data Analysis Software Toolkit for Advanced Analytics of DNA and RNA Editing Efficiency and Outcomes for Therapeutic Development at the ASGCT 25th Annual Meeting
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BEIJING and CAMBRIDGE, MASS. – (May 2, 2022) – EdiGene, Inc., a global, clinical-stage biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, will present getools (gene editing data analysis toolkit) for advanced analytics of DNA and RNA editing efficiency and outcomes for therapeutic development at the American Society of Gene & Cell Therapy (ASG
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding EdiGene
Sign Up For FreeTo access detailed company insights
EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. Established in 2015, EdiGene is headquartered in Beijing, China.... Read More
